You are here: Home » News-IANS » Health-Medicine
Business Standard

Fibrosis plays a role in ageing

IANS  |  London 

Fibrosis, which mostly affects the lungs and hepatic tissues, accounts for up to 45 per cent of deaths in the developed world yet till date no effective therapeutic treatment has been developed, says a recent study.

Fibrosis, one of the age-related pathologies that disrupt organ functionality dramatically, is a progressive accumulation of extra-cellular matrix which occurs in a wide range of organs and potentially distort their structure and function.

Researchers at the US-based Insilico Medicine Inc utilised a new software tool to identify robust bio-markers of fibrotic disease and develop effective targeted therapy.

"Fibrosis is one of the age-related pathologies that disrupt organ functionality dramatically. Currently, there are no approved anti-fibrotic remedy and no reliable fibrotic bio-marker," said Eugene Makarev, Vice-President, Insilico Medicine Inc at Baltimore, in the study published in the journal of Cell Cycle.

The researchers utilised the new software tool referred to as "Regeneration Intelligence" to evaluate the perturbation status of many signalling pathways.

This new system aimed to identify robust bio-markers of fibrotic disease and develop effective targeted therapy.

"Despite many efforts, fibrosis is often mis-diagnosed. Our system is supposed to help with proper and timely diagnostic," added Makarev.

"Regeneration Intelligence" is a system that can detect hidden fibrotic molecular signatures based on a pathway network analysis.

The system can identify specific fibrogenic molecular changes regardless of detecting platform and tissue of origin.

With broad screening across multiple fibrotic organs, the system identified pathogenic pathways that served as potential targets for the anti-fibrotic therapy.

This approach led to a selection of the list of small molecules and natural compounds by their ability to minimise the signalling pathway difference between a fibrotic and a healthy state of the tissue.



Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, July 31 2016. 19:08 IST